Cargando…

Corrigendum to “Therapeutic effect of ursolic acid in experimental visceral leishmaniasis” [Int. J. Parasitol. Drugs Drug Resist. 7 (2017) 1–11]

Detalles Bibliográficos
Autores principales:	Jesus, Jessica A., Fragoso, Thais N., Yamamoto, Eduardo S., Laurenti, Marcia D., Silva, Marcelo S., Ferreira, Aurea F., Lago, João Henrique G., Santos-Gomes, Gabriela, Passero, Luiz Felipe D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114079/ https://www.ncbi.nlm.nih.gov/pubmed/28433520 http://dx.doi.org/10.1016/j.ijpddr.2017.04.001

Ejemplares similares

Therapeutic effect of ursolic acid in experimental visceral leishmaniasis
por: Jesus, Jéssica A., et al.
Publicado: (2016)

Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis
por: Jesus, Jéssica Adriana, et al.
Publicado: (2020)

Preclinical Assessment of Ursolic Acid Loaded into Nanostructured Lipid Carriers in Experimental Visceral Leishmaniasis
por: Jesus, Jéssica Adriana, et al.
Publicado: (2021)

Corrigendum to “Rational approach to drug discovery for human schistosomiasis” [Int. J. Parasitol. Drugs Drug Resist. 16 (2021) 140–147]
por: LoVerde, Philip T., et al.
Publicado: (2022)

Antimicrobial Activity of Oleanolic and Ursolic Acids: An Update
por: Jesus, Jéssica A., et al.
Publicado: (2015)

Corrigendum to “Genetic diversity of next generation antimalarial targets: A baseline for drug resistance surveillance programmes” [Int. J. Parasitol. Drugs and Drug Resist. 7 (2017) 174–180]
por: Gomes, Ana Rita, et al.
Publicado: (2017)

Related Pentacyclic Triterpenes Have Immunomodulatory Activity in Chronic Experimental Visceral Leishmaniasis
por: de Jesus, Jéssica Adriana, et al.
Publicado: (2021)

Dear Editor-in-Chief Iranian J Parasitol
por: Gholami, SH
Publicado: (2012)

Erratum to “Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites” [Int. J. Parasitol. Drugs Drug Res. 5 (2015) 117–126]
por: Engel, Jessica A., et al.
Publicado: (2016)

Reply: Dear Editor-in-Chief Iranian J Parasitol
por: Fakhar, Mahdi
Publicado: (2012)

Clarification on a Published Paper in Iran J Parasitol
por: DEGERLI, Serpil, et al.
Publicado: (2015)

Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
por: Bezerra-Souza, Adriana, et al.
Publicado: (2019)

The Effect of Ursolic Acid on Leishmania (Leishmania) amazonensis Is Related to Programed Cell Death and Presents Therapeutic Potential in Experimental Cutaneous Leishmaniasis
por: Yamamoto, Eduardo S., et al.
Publicado: (2015)

Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis
por: Bilbao-Ramos, Pablo, et al.
Publicado: (2020)

Corrigendum to ‘the anti-fecundity effect of 5-azacytidine (5-AzaC) on Schistosoma mansoni is linked to dis-regulated transcription, translation and stem cell activities’ [Int. J. Parasitol. Drugs and Drug Resist. 8 (2018) 213–222]
por: Geyer, Kathrin K., et al.
Publicado: (2018)

Drug Resistance in Visceral Leishmaniasis
por: Maltezou, Helena C.
Publicado: (2010)

Corrigendum to “Exposure of vaccinated and naive cattle to natural challenge from buffalo-derived Theileria parva” [Int. J. Parasitol. Parasites Wildl. 4(2) (2015) 244–251]
por: Sitt, Tatjana, et al.
Publicado: (2017)

Visceral leishmaniasis: Experimental models for drug discovery
por: Gupta, Suman, et al.
Publicado: (2011)

Evaluating drug resistance in visceral leishmaniasis: the challenges
por: HENDRICKX, S, et al.
Publicado: (2018)

Int Braz J Urol Annual Report - 2017
Publicado: (2018)

Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis
por: Bezerra-Souza, Adriana, et al.
Publicado: (2021)

Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015)

Elevated TGF-beta levels in drug-resistant visceral leishmaniasis
por: Elmekki, Miskelyemen A., et al.
Publicado: (2016)

In situ CUTANEOUS CELLULAR IMMUNE RESPONSE IN DOGS NATURALLY AFFECTED BY VISCERAL LEISHMANIASIS
por: ROSSI, Claudio Nazaretian, et al.
Publicado: (2016)

Epidemiology of visceral leishmaniasis
por: Ready, Paul D
Publicado: (2014)

Serological and infection statuses of dogs from a visceral leishmaniasis-endemic area
por: Laranjeira, Daniela Farias, et al.
Publicado: (2014)

Human visceral leishmaniasis: epidemiological, temporal and spacial aspects in Northeast Brazil, 2003-2017
por: Cavalcante, Francisco Roger Aguiar, et al.
Publicado: (2020)

Treatment of Visceral Leishmaniasis
por: Moore, E M, et al.
Publicado: (2010)

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis
por: Wyllie, Susan, et al.
Publicado: (2018)

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2016)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Expression of inducible nitric oxide synthase in macrophages inversely correlates with parasitism of lymphoid tissues in dogs with visceral leishmaniasis
por: Sanches, Françoise P, et al.
Publicado: (2014)

Prevalence and incidence of canine visceral leishmaniasis and its clinical–immunological features in an endemic area of the Brazilian Amazon
por: Carneiro, Liliane A., et al.
Publicado: (2023)

Leishmanicidal Activity and Ultrastructural Changes of Maslinic Acid Isolated from Hyptidendron canum
por: Adriana Jesus, Jéssica, et al.
Publicado: (2021)

Therapeutic Activity of a Topical Formulation Containing 8-Hydroxyquinoline for Cutaneous Leishmaniasis
por: de Lima, Sarah Kymberly Santos, et al.
Publicado: (2023)

Water-soluble polymer–drug conjugates for combination chemotherapy against visceral leishmaniasis
por: Nicoletti, Salvatore, et al.
Publicado: (2010)

A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery
por: Álvarez-Velilla, Raquel, et al.
Publicado: (2019)

Exposure to Leishmania spp. infection and Lutzomyia spp. in individuals living in an area endemic for visceral leishmaniasis in Brazil
por: Hirata, Karina Yukie, et al.
Publicado: (2019)

Congenital Visceral Leishmaniasis
por: Boehme, Catharina C., et al.
Publicado: (2006)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hapisiree7idb0r4u4nofb288t